leisure time -WSS

leisure time

author：hotspot 2025-08-12 09:11:14 - browse：371

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Gilgo Beach: Police identify another victim in serial killing investigation

focus

hotspot

WSS

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

North Korean leader's powerful sister says warplanes repelled US spy plane

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Humana, CVS hope to turn members into patients at clinics

entertainment

leisure time

explore

After affirmative action ruling, medical educators look to 'holistic review'

How corporate America is slashing DEI workers amid backlash to diversity programs

Continuity nursing helped my family in our darkest PICU moments

Attacks on the drug industry will lead to fewer breakthroughs

DIEP, the 'gold standard' of breast reconstruction, is under threat

Verily hires former Apple Health leader as chief scientific officer

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Sports medicine is finally prioritizing gender equality

Stem cell clinics for heart failure: buyer be wary

explore

UPS workers' union leader explains what's at stake as strike edges closer

Why Titanic fascinates society, still drawing tours to the wreckage

California man arrested in connection with serial murders of Mexican strip club workers

Drinking water from half of US faucets contains PFAS: Study

ProMED, early warning system on disease outbreaks, in peril

Sen. Bill Cassidy on how to lower drug prices

focus

knowledge

hotspot

hotspot